Anthem Biosciences Q1 revenue falls 23% as growth streak stalls
Revenue of **₹418 crore** down from **₹540 crore** a year earlier; net profit slips **12%** to **₹120 crore**. CRDMO segment contributes **₹341 crore**, specialty ingredients **₹77 crore**.
— 3 earlier stories on Anthem Biosciences Ltd. →What's new
- Consolidated revenue fell 22.6% YoY to ₹418 crore.
- CRDMO segment contributed ₹341 crore; specialty ingredients ₹77 crore.
- Net profit dropped 12% to ₹120 crore from ₹136 crore.
Why this matters
The drop breaks a strong growth streak; trailing revenue growth was 26.4%. But this quarter is backward-looking and the market prices results quickly. The investment case now hinges on the ₹1,200 crore GLP-1 plant expansion, not a single quarter's numbers.
What we're watching
- Management's outlook on demand trends for CRDMO and specialty ingredients.
- Progress on the Phase 1 Unit 4 GLP-1 plant commissioning.
- Whether the revenue decline is a one-off or signals structural headwinds.
The full read
Anthem Biosciences reported Q1 revenue of ₹418 crore, down 22.6% from a year earlier. Hardly a crisis. Net profit fell 12% to ₹120 crore, with CRDMO contributing ₹341 crore and specialty ingredients ₹77 crore. The market had already priced these numbers in, and the analyst rationale calls the quarter backward-looking — it does not alter the long-term thesis. What does change the narrative is the ₹1,200 crore GLP-1 plant expansion announced in May. One soft quarter does not rewrite that thesis, but it raises the bar for delivery.
Questions answered
- What drove the 22.6% revenue decline?
- The filing does not specify the cause. The CRDMO segment contributed ₹341 crore and specialty ingredients ₹77 crore, but prior-year comparatives for segments are not disclosed.
- How does Q1 compare to the previous (Mar 2026) quarter?
- The filing only provides year-ago comparisons. Sequential data is not available in this release.
- What is Anthem's current capital expenditure plan?
- In May 2026, the company announced a ₹1,200 crore investment for a new Phase 1 Unit 4 expansion targeting GLP-1 production.
- Did any promoter sell shares recently?
- Yes, a promoter group member sold their entire 3.05% direct holding in June 2026.
Anthem Biosciences Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on ANTHEM →- 21 Jul 2026 · 4:40 PM IST Anthem Biosciences Q1 revenue falls 23% as growth streak stalls
- 1d ago Anthem Q1 transcript adds nothing new to already-known results
- 39d ago Anthem Biosciences promoter group member sells entire 3.05% stake
- 67d ago Anthem Biosciences bets ₹1,200 cr on GLP-1 plant expansion